HOOK · HOOKIPA Pharma Inc.
Substantial doubt about the company's ability to continue as a going concern.
“As of the filing date of this Quarterly Report on Form 10-Q, the Company's expectation to generate negative operating cash flows in the future and the need for additional funding to support its planned operations raise substantial doubt regarding the Company's ability to continue as a going concern for a period of one year after the date that these condensed consolidated financial statements are issued.”View the 10-Q filed May 15, 2025
Trades by corporate insiders — officers, directors and holders of more than 10% of the shares — disclosed to the SEC on Forms 3, 4 and 5. Form 4 must be filed within two business days of the trade.
| Date | Insider | Role | Type | Security | Shares |
|---|---|---|---|---|---|
| 2025-08-19 | Peters Malte |
Director, Chief Executive Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.8205 to $0.8225 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Common Stock
|
25,172 |
| 2025-07-22 | Peters Malte |
Director, Chief Executive Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
This sale was affected pursuant to a "sell to cover" arrangement adopted by the Issuer to satisfy the tax withholding obligations triggered by the vesting of restricted stock units granted on July 22, 2024 and does not represent a discretionary trade by the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. |
Common Stock
|
29,176 |
| 2025-07-22 | Coelho Mary Theresa |
Director, EVP and CFO |
Sell↓
Filing footnotes — Common Stock (Direct)
This sale was affected pursuant to a "sell to cover" arrangement adopted by the Issuer to satisfy the tax withholding obligations triggered by the vesting of restricted stock units granted on July 22, 2024 and does not represent a discretionary trade by the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. |
Common Stock
|
13,609 |
| 2024-07-22 | Cassidy Sean A |
Director |
Other↑
|
No Securities Owned
|
0 |
| 2024-07-22 | Cassidy Sean A |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The shares subject to this option will vest in thirty-six equal monthly installments commencing July 22, 2024, subject to Reporting Person's continuous service through each such date. |
Stock Option (Right to Buy)
|
9,800 |
| 2024-07-22 | Coelho Mary Theresa |
Director, EVP and CFO |
Award↑
Filing footnotes — Common Stock (Direct)
Grant to the Reporting Person of a restricted stock unit ("RSU") award. Each RSU represents a contingent right to receive one share of common stock of the Issuer. The RSU shall vest in two equal installments on July 22, 2025 and July 22, 2026, subject to the Reporting Person's continuous service through each such date. |
Common Stock
|
69,875 |
| 2024-07-22 | Peters Malte |
Director, Chief Executive Officer |
Award↑
Filing footnotes — Common Stock (Direct)
Grant to the Reporting Person of a restricted stock unit ("RSU") award. Each RSU represents a contingent right to receive one share of common stock of the Issuer. The RSU shall vest in two equal installments on July 22, 2025 and July 22, 2026, subject to the Reporting Person's continuous service through each such date. |
Common Stock
|
108,695 |
| 2024-06-17 | Peters Malte |
Director, Chief Executive Officer |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
This option award shall vest and become fully exercisable on the earlier to occur of (a) June 17, 2025 and (b) the date of the Issuer's next annual meeting of its stockholders. |
Stock Option (Right to Buy)
|
49,000 |
| 2024-06-17 | Coelho Mary Theresa |
Director, EVP and CFO |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
This option award shall vest and become fully exercisable on the earlier to occur of (a) June 17, 2025 and (b) the date of the Issuer's next annual meeting of its stockholders. |
Stock Option (Right to Buy)
|
49,000 |
| 2024-06-17 | Reilly Timothy P. |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
This option award shall vest and become fully exercisable on the earlier to occur of (a) June 17, 2025 and (b) the date of the Issuer's next annual meeting of its stockholders. |
Stock Option (Right to Buy)
|
49,000 |
| 2024-06-17 | van de Winkel Jan |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
This option award shall vest and become fully exercisable on the earlier to occur of (a) June 17, 2025 and (b) the date of the Issuer's next annual meeting of its stockholders. |
Stock Option (Right to Buy)
|
98,000 |
| 2024-06-17 | O'Neill Julie |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
This option award shall vest and become fully exercisable on the earlier to occur of (a) June 17, 2025 and (b) the date of the Issuer's next annual meeting of its stockholders. |
Stock Option (Right to Buy)
|
49,000 |
| 2024-06-17 | Kaufman David Ross |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
This option award shall vest and become fully exercisable on the earlier to occur of (a) June 17, 2025 and (b) the date of the Issuer's next annual meeting of its stockholders. |
Stock Option (Right to Buy)
|
49,000 |
| 2024-04-15 | Orlinger Klaus |
Chief Scientific Officer |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
25% of this option shall vest on April 15, 2025, with the remainder vesting in 12 equal quarterly installments thereafter. |
Stock Option (Right to Buy)
|
367,300 |
| 2024-04-15 | Winderlich Mark |
Chief Development Officer |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
25% of this option shall vest on April 15, 2025, with the remainder vesting in 12 equal quarterly installments thereafter. |
Stock Option (Right to Buy)
|
250,000 |
| 2024-04-15 | Aldag Jorn |
Director, Chief Executive Officer |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
25% of this option shall vest on April 15, 2025, with the remainder vesting in 12 equal quarterly installments thereafter. |
Stock Option (Right to Buy)
|
971,400 |
| 2024-04-15 | Necina Roman |
Chief Operations Officer |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
25% of this option shall vest on April 15, 2025, with the remainder vesting in 12 equal quarterly installments thereafter. |
Stock Option (Right to Buy)
|
367,300 |
| 2024-04-15 | Kandera Reinhard |
Director, Chief Financial Officer |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
25% of this option shall vest on April 15, 2025, with the remainder vesting in 12 equal quarterly installments thereafter. |
Stock Option (Right to Buy)
|
406,200 |
| 2024-04-15 | Winderlich Mark |
Chief Development Officer |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
25% of this option shall vest on April 15, 2025, with the remainder vesting in 12 equal quarterly installments thereafter. |
Stock Option (Right to Buy)
|
50,000 |
| 2024-04-01 | Winderlich Mark |
Chief Development Officer |
Other↑
|
No Securities Owned
|
0 |
| 2023-08-21 | Kandera Reinhard |
Director, Chief Financial Officer |
Buy↑
|
Common Stock
|
7,000 |
| 2023-08-16 | Kandera Reinhard |
Director, Chief Financial Officer |
Buy↑
|
Common Stock
|
8,000 |
| 2023-07-11 | Aldag Jorn |
Director, Chief Executive Officer |
Buy↑
|
Common Stock
|
5,000 |
| 2023-07-07 | Aldag Jorn |
Director, Chief Executive Officer |
Buy↑
|
Common Stock
|
5,000 |
| 2023-07-05 | Aldag Jorn |
Director, Chief Executive Officer |
Buy↑
|
Common Stock
|
5,000 |
| 2023-07-03 | Aldag Jorn |
Director, Chief Executive Officer |
Buy↑
|
Common Stock
|
5,000 |
| 2023-06-30 | Kandera Reinhard |
Director, Chief Financial Officer |
Buy↑
|
Common Stock
|
12,000 |
| 2023-06-09 | van de Winkel Jan |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
This option shall vest and become fully exercisable on the earlier to occur of (a) June 9, 2024 and (b) the date of the Issuer's 2024 annual meeting of its stockholders. |
Stock Option (Right to Buy)
|
52,000 |
| 2023-06-09 | Peters Malte |
Director, Chief Executive Officer |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
One-third of this option shall vest on June 9, 2024, with the remainder vesting in 8 equal quarterly installments thereafter. |
Stock Option (Right to Buy)
|
52,000 |
| 2023-06-09 | Coelho Mary Theresa |
Director, EVP and CFO |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
One-third of this option shall vest on June 9, 2024, with the remainder vesting in 8 equal quarterly installments thereafter. |
Stock Option (Right to Buy)
|
52,000 |
| 2023-06-09 | Kaufman David Ross |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
This option shall vest and become fully exercisable on the earlier to occur of (a) June 9, 2024 and (b) the date of the Issuer's 2024 annual meeting of its stockholders. |
Stock Option (Right to Buy)
|
26,000 |
| 2023-06-09 | O'Neill Julie |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
This option shall vest and become fully exercisable on the earlier to occur of (a) June 9, 2024 and (b) the date of the Issuer's 2024 annual meeting of its stockholders. |
Stock Option (Right to Buy)
|
26,000 |
| 2023-06-09 | Reilly Timothy P. |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
This option shall vest and become fully exercisable on the earlier to occur of (a) June 9, 2024 and (b) the date of the Issuer's 2024 annual meeting of its stockholders. |
Stock Option (Right to Buy)
|
26,000 |
| 2023-04-14 | Orlinger Klaus |
Chief Scientific Officer |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
25% of this option shall vest on February 15, 2024, with the remainder vesting in 12 equal quarterly installments thereafter. |
Stock Option (Right to Buy)
|
194,200 |
| 2023-04-14 | Schlienger Katia |
Chief Medical Officer |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
25% of this option shall vest on February 15, 2024, with the remainder vesting in 12 equal quarterly installments thereafter. |
Stock Option (Right to Buy)
|
184,000 |
| 2023-04-14 | Kandera Reinhard |
Director, Chief Financial Officer |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
25% of this option shall vest on February 15, 2024, with the remainder vesting in 12 equal quarterly installments thereafter. |
Stock Option (Right to Buy)
|
214,800 |
| 2023-04-14 | Necina Roman |
Chief Operations Officer |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
25% of this option shall vest on February 15, 2024, with the remainder vesting in 12 equal quarterly installments thereafter |
Stock Option (Right to Buy)
|
112,100 |
| 2023-04-14 | Aldag Jorn |
Director, Chief Executive Officer |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
25% of this option shall vest on February 15, 2024, with the remainder vesting in 12 equal quarterly installments thereafter. |
Stock Option (Right to Buy)
|
513,600 |
| 2023-04-14 | Baker Christine D. |
Chief Operating Officer |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
25% of this option shall vest on February 15, 2024, with the remainder vesting in 12 equal quarterly installments thereafter. |
Stock Option (Right to Buy)
|
275,800 |
| 2023-04-03 | Coelho Mary Theresa |
Director, EVP and CFO |
Other↑
|
No Securities Owned
|
0 |
| 2023-01-01 | Peters Malte |
Director, Chief Executive Officer |
Other↑
|
No Securities Owned
|
0 |
| 2022-06-30 | O'Neill Julie |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
This option shall vest and become fully exercisable on June 30, 2023. |
Stock Option (Right to Buy)
|
20,000 |
| 2022-06-30 | Reilly Timothy P. |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
This option shall vest and become fully exercisable on June 30, 2023. |
Stock Option (Right to Buy)
|
40,000 |
| 2022-06-30 | van de Winkel Jan |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
This option shall vest and become fully exercisable on June 30, 2023. |
Stock Option (Right to Buy)
|
40,000 |
| 2022-06-30 | Matushansky Igor |
Chief Medical Officer |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
25% of this option shall vest on April 19, 2023, with the remainder vesting in 12 equal quarterly installments thereafter. |
Stock Option (Right to Buy)
|
92,950 |
| 2022-06-30 | Orlinger Klaus |
Chief Scientific Officer |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
25% of this option shall vest on April 19, 2023, with the remainder vesting in 12 equal quarterly installments thereafter. |
Stock Option (Right to Buy)
|
48,350 |
| 2022-06-30 | Necina Roman |
Chief Operations Officer |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
25% of this option shall vest on April 19, 2023, with the remainder vesting in 12 equal quarterly installments thereafter. |
Stock Option (Right to Buy)
|
48,350 |
| 2022-06-30 | Kelly Michael Aaron |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
This option shall vest and become fully exercisable on June 30, 2023. |
Stock Option (Right to Buy)
|
20,000 |
| 2022-06-30 | Baker Christine D. |
Chief Operating Officer |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
25% of this option shall vest on April 19, 2023, with the remainder vesting in 12 equal quarterly installments thereafter. |
Stock Option (Right to Buy)
|
100,000 |
| 2022-06-30 | Kandera Reinhard |
Director, Chief Financial Officer |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
25% of this option shall vest on April 19, 2023, with the remainder vesting in 12 equal quarterly installments thereafter. |
Stock Option (Right to Buy)
|
92,950 |